Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Resilient Bacteria May Be Treatable with Currently-Available Therapies

By LabMedica International staff writers
Posted on 29 Jan 2020
Bacteria develop defenses against hostile elements in their environment. More...
One common tactic is "tolerance," that is, lying dormant during antibiotic treatment. In this way, bacteria evade antibiotic treatment because antibiotics can only spot and kill growing targets.

However, this intermediary stage called "antibiotic tolerance" lasts only a few days and cannot be detected in standard medical laboratories. Therefore, doctors miss the tolerance window and with it the opportunity to treat a serious infection before it becomes altogether resistant. This short window does not affect most healthy adults, but for those patients fighting off a blood infection with a weakened immune system, this window is critical and could mean the difference between life and death.

Scientists at The Hebrew University of Jerusalem (Jerusalem, Israel) and their colleagues developed a mathematical model that successfully described, measured and predicted when bacteria would develop tolerance to a particular antibiotic. Further, they observed that when bacteria developed tolerance to one antibiotic, they were more likely to develop tolerance to other antibiotics in the cocktail. They have analyzed daily bacterial samples from hospitalized patients with life-threatening, persistent methicillin-resistant Staphylococcus aureus (MRSA) infections.

The investigators detected the rapid emergence of tolerance mutations, followed by the emergence of resistance, despite the combination treatment. Evolution investigations on the clinical strains in vitro revealed a new way by which tolerance promotes the evolution of resistance under combination treatments. Further, in the study, under different antibiotic classes reveal the generality of the effect. The team believes that the same evolutionary processes involved in the development of antibiotic tolerance and resistance are likely at play in cancer and might be used to inform treatment. For example, tumor cells might first become tolerant of chemotherapy, develop resistance to it, and then develop resistance to other cancer drugs, as well.

Nathalie Q. Balaban, PhD, a professor and the senior author of the study, said, “We observed that bacteria acquired tolerance within a few days. These tolerance mutations then acted as a stepping stone to acquire resistance and, ultimately, treatment failure. Using the right combination of available antibiotic drugs at the outset could dramatically increase a patients' survival rate before their infection becomes tolerant to all the antibiotics in our arsenal.” The study was published on January 10, 2020 in the journal Science.

Related Links:
The Hebrew University of Jerusalem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.